FLEURY S.A. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 14.61 BRL | +4.28% |
|
+4.06% | -19.01% |
| 08/03 | Transcript : Fleury S.A., Q4 2023 Earnings Call, Mar 08, 2024 | |
| 07/03 | Fleury S.A. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 | CI |
Summary
- According to Refinitiv, the company's ESG score for its industry is good.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The company has a low valuation given the cash flows generated by its activity.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- Revenue estimates are regularly revised downwards for the current and coming years.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -19.01% | 1.55B | A- | ||
| -17.89% | 8.25B | B+ | ||
| +39.20% | 3.58B | C+ | ||
| -39.11% | 2.46B | B- | ||
| -8.06% | 2.46B | - | ||
| -7.35% | 2.38B | B- | ||
| -40.66% | 1.21B | C+ | ||
| +7.56% | 1.11B | B+ | ||
| -15.34% | 1.03B | - | - | |
| -16.56% | 878M | C |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- FLRY3 Stock
- Ratings Fleury S.A.
